Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Systemic Sclerosis (Scleroderma) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

- New Phase I study to evaluate drug-drug interactions could allow nintedanib to be administered concomitantly with relevant birth-control pills, potentially increasing the eligible patient population for nintedanib
- Corbus Pharmaceuticals continues to present data for lenabasum at rheumatology conferences, as the company attempts to increase awareness of its late stage pipeline candidate, which could facilitate patient recruitment to its ongoing Phase III RESOLVE-1 trial
- Completion of recruitment for SAR-156597's Phase II trial was confirmed ahead of its expected primary completion in Q4 2018.

Scope

- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Companies Mentioned
Actelion
Active Biotech
arGentis Pharmaceuticals
Assistance Publique - Hôpitaux de Paris
AstraZeneca
Bayer
Biogen
BMS
Boehringer Ingelheim
Celgene
Corbus Pharmaceuticals
CSL Behring
Cumberland Pharmaceuticals
Cytori
Daval International
Digna Biotech
EMD Serono & Merck KGaA
Emerald Health Pharmaceuticals
Fibrocell Science; Intrexon Corporation
Fred Hutchinson Cancer Research Center
Genentech (collaborator)
Gilead
GSK
Human Stem Cells Institute
iBio
Inventiva Pharma
Kadmon
miRagen
Novartis
Pfizer
Regeneron, Boston University
Roche
Samumed
Sanofi
Seattle Genetics
United Therapeutics
University of Pittsburgh